FindTrial
Sign In

A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients with Moderate-to-Severe Psoriasis

A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients with Moderate-to-Severe Psoriasis

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221846
Enrollment
Unknown
Registered
2012-07-04
Start date
2012-07-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

investigational material(s) Generic name etc : LY2439821 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: male or female patients aged 20 years or older who have the following: Chronic Ps based on a confirmed diagnosis for at least 6 months prior to baseline (Week 0; Visit 2), a PASI score no less than 12, an sPGA score of no less than 3, and have no less than 10% BSA involvement at both Screening (Visit 1) and baseline (Week 0; Visit 2) Are candidates for phototherapy and/or systemic therapy

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026